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Abstract
Background—The magnitude of risk conferred by the interaction between tobacco and alcohol
use on the risk of head and neck cancers is not clear, since studies have used various methods to
quantify the excess head and neck cancer burden.
Methods—We analyzed individual-level pooled data from 17 European and American case-
control studies (11,221 cases and 16,168 controls) participating in the International Head and
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Neck Cancer Epidemiology (INHANCE) consortium. We estimated the multiplicative interaction
parameter (ψ) and population attributable risks (PAR).
Results—A greater than multiplicative joint effect between ever tobacco and alcohol use was
observed for head and neck cancer risk (ψ=2.15, 95%CI=1.53–3.04). The PAR for tobacco or
alcohol was 72% (95%CI=61%–79%) for head and neck cancer, of which 4% was due to alcohol
alone, 33% was due tobacco alone and 35% was due to tobacco and alcohol combined. The total
PAR differed by subsite (64% for oral cavity cancer, 72% for pharyngeal cancer, 89% for
laryngeal cancer), by sex (74% for men, 57% for women) by age (33% for cases <45 years, 73%
for cases >60 years) and by region (84% in Europe, 51% in North America, 83% in Latin
America).
Conclusions—Our results confirm that the joint effect between tobacco and alcohol use is
greater than multiplicative on head and neck cancer risk. However, a substantial proportion of
head and neck cancers cannot be attributed to tobacco or alcohol use, particularly for oral cavity
cancer, for head and neck cancer among women and among young onset cases.
Introduction
Over half a million head and neck cancer cases occur each year and is a significant cause of
morbidity and mortality(1). The interaction between tobacco and alcohol use is important for
head and neck cancer risk (2). Numerous epidemiologic studies have examined the
interaction between tobacco and alcohol and the risk of head and neck cancers, but many
reports assessed interactions only descriptively, without applying formal statistical testing
(2). Some studies tested for the presence of interactions on the additive scale while others
tested on the multiplicative scale, and different categories were used for tobacco use and
alcohol use. These results are therefore difficult to compare across studies. Due to these
limitations, the magnitude of head and neck cancer risk conferred by the interaction between
tobacco and alcohol is not clear. Furthermore, it is unknown whether interactions differ by
subsite, sex, age or geographic region. Finally, the proportion of cases which can be
attributed to tobacco alone, alcohol alone, and tobacco and alcohol combined has not been
estimated precisely. Better estimation of attributable risks for tobacco and alcohol may
clarify the importance of other known or potential risk factors such as Human
Papillomavirus (HPV), high body mass index (BMI) or family history of head and neck
cancer.
To evaluate the interaction between tobacco and alcohol and the risk of head and neck
cancer, we conducted a pooled analysis within the International Head and Neck Cancer
Epidemiology (INHANCE) consortium. Our aim was to (i) formally test the multiplicative
model of interaction between alcohol and tobacco use with a very large sample size, (ii) to
assess the population attributable risk (PAR) due to the effects of alcohol alone, tobacco
alone and tobacco and alcohol combined, and (iii) to examine whether there is heterogeneity
in the estimates for interactions by head and neck cancer subsite, as well as due to potential
effect modifiers such as sex, age, and geographic region.
Methods
The International Head and Neck Cancer Epidemiology (INHANCE) Consortium
(http://inhance.iarc.fr/) was established in 2004, based on the collaboration of research
groups leading large epidemiology studies of head and neck cancer that are on-going or have
been recently completed. We pooled the data from 18 individual case-control studies
(version 1.1), including 12,282 cases and 17,189 controls (3–19). Compared to our previous
publication (20), the current dataset added a Rome study(5), New York multicenter
study(14) and Boston study(16). In this current analysis, we excluded from the analyses a
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French study (323 cases and 234 controls) that was restricted to regular smokers (4) and the
Sudan (106 cases and 151 controls) and India (576 cases and 582 controls) centers of the
International Multicenter study(12) because of the small number of subjects to represent
these regions for estimation of population attributable risks. Additionally in India, contrary
to other countries, betel quid and areca nut chewing are major contributors to attributable
fractions of oral cavity cancer.
Characteristics of the individual studies are presented in table 1 in the appendix. Most were
hospital-based case-control studies and frequency matched their controls to the cases on age,
sex and additional factors (study center, hospital, race/ethnicity). The Los Angeles study
individually matched the control subjects to case subjects on age decade, gender and
neighborhood, though in the analysis the matching was broken. Face-to-face interviews were
conducted in all studies except for the Iowa study, in which subjects completed self-
administered questionnaires.
Written informed consent was obtained from all study subjects and the investigations were
approved by institutional review boards at each of the institutes involved. Questionnaires
were collected from all the individual studies, to assess the comparability of the collected
data and of the wording of interview questions among the studies. Data from individual
studies were received at the International Agency for Research on Cancer (IARC) with
personal identifiers removed. Each data item was checked for illogical or missing values and
inconsistencies were resolved as necessary.
Cases and controls with missing data on age, sex, or race/ethnicity, and cases with missing
information on the site of origin of their cancer were excluded (56 cases and 54 controls).
Cases were included in this study if their tumor had been classified by the original study as
an invasive tumor of oral cavity, oropharynx, hypopharynx, oral cavity or pharynx not
otherwise specified (NOS), larynx, or head and neck cancer unspecified. Subjects with
cancers of the major salivary glands (parotid, submandibular, or sublingual glands; ICD-O-2
codes C07-C08), or of the nasal cavity/ear/paranasal sinuses (ICD-O-2 codes C30-C31)
were excluded from the analysis. The ICD coding used for the classification into subsites
was specified in detail previously(20). Thus the data for this analysis included 11,221 head
and neck cancer cases and 16,168 controls from 17 studies. There were a total of 2,993 oral
cavity cancer cases, 4,040 oropharyngeal and hypopharyngeal cancer cases (pharyngeal),
917 unspecified oral cavity/pharynx cases, 2,965 laryngeal cancer cases and 306 unspecified
head and neck cancer cases. We focused our site-specific analyses on oral cavity, pharyngeal
and laryngeal cancers. Three of the studies did not collect information on tumor histology.
Of the studies that collected histology, 86.7% (8034/9265) of head and neck cancer cases
were squamous cell carcinoma (SCC).
The questions about tobacco smoking and alcohol drinking in the study questionnaires were
conceptually similar across studies, although the exact wording differed. The questions
about tobacco and alcohol use were examined carefully for comparability before variables
were created for this analysis (definitions for being a cigarette, cigar, or pipe smoker for
each study are provided in the appendix). Variables on the frequency (i.e., number of
cigarettes, cigars, or pipes smoked per day), duration (in years), and pack-years (i.e.,
cumulative smoking) of tobacco smoking were available in all studies.
Information about snuff use and chewing habits was collected by the Puerto Rico study, the
International multicenter studies, and all studies in North America. Snuff use and chewing
are not common behaviors in Europe or Latin America, except in specific populations (e.g.,
Norway and Sweden) that were not included in the pooled dataset (definitions of ever
chewing and ever use of snuff are provided in the appendix). Frequency and duration
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variables for chewing and snuff use habits were pooled across relevant studies. For this
study, never users of tobacco were defined as individuals who had not used cigarettes,
cigars, pipes, snuff, or chewing products during their lifetimes. A combined tobacco
frequency variable was created, where ever tobacco users were categorized as having used
1–20 cigarettes, 1–20 cigars, 1–20 pipes, 1–2 chewing products or 1–2 snuff units per day,
or >20 cigarettes, >20 cigars, >20 pipes, >2 chewing products or >2 snuff units per day.
In the alcohol section of the study questionnaires, subjects were asked if they were alcohol
drinkers (definitions by study in appendix); for those who responded that they were,
subsequent questions were asked about the frequency of drinking, the duration of drinking,
and the different types of alcoholic beverages consumed (i.e., beer, wine, hard liquors, and/
or aperitif). Details on the pooling of frequency and duration variables on alcohol are
provided in the appendix.
Statistical methods
The interactions between tobacco and alcohol on the risk of head and neck cancer were
assessed by estimating odds ratios (ORs) and 95% confidence intervals (95%CIs) using
unconditional logistic regression models for each study. To assess interactions on the
multiplicative scale, we estimated odds ratios for joint effects (OR11= OR for ever tobacco/
ever alcohol use, OR01=OR for never tobacco/ever alcohol use, OR10 = OR for ever
tobacco/never alcohol use). The multiplicative interaction parameters & 95%CIs [ψ=OR11/
(OR01 * OR10)] were also estimated by including variables for ever alcohol use, ever
tobacco use and a product term (equivalent to the multiplicative interaction parameter) of
those two variables in the logistic regression model. ψ>1 is suggestive of a joint effect that is
greater than expected under the multiplicative model. When a joint effect greater than
multiplicative was not observed, interactions on the additive scale were assessed with
relative excess risk due to interaction (RERI), attributable proportion (AP, proportion of
disease among those with both exposures that is attributable to their interaction) and synergy
index (SI)(21). We estimated 95% confidence intervals for each of these measures. The null
values of RERI and AP are 0, while the null value for SI is 1.
The logistic regression models included age (<40 years, 40–44 years, 45–49 years, 50–54
years, 55–59 years, 60–64 years, 65–69 years, 70–74 years, or ≥75 years), sex, education
level (no formal education, less than junior high school, some high school, high school
graduate, vocational/some college, or college graduate/postgraduate), race/ethnicity (non-
Hispanic white, Black, Hispanic/Latino, Asian/Pacific Islander, other, Latin American), and
study center to adjust for potential confounders. We tested for heterogeneity among the
study ORs by conducting a likelihood ratio test comparing a model including the product
terms between each study (other than the reference study) with the variable of interest and a
model without the product terms (degrees of freedom = number of studies −1), for the risk
of head and neck cancer combined and for the risk of each of these head and neck cancer
subsites. Heterogeneity was detected consistently; therefore, to calculate the summary
estimates of association, the study-specific estimates were included in a two-stage random
effects logistic regression model with between-study variability and the common odds ratio
being estimated using maximum likelihood estimation.
Information on ethnicity was not collected in the Central Europe and Latin America studies.
In the Central Europe study, all subjects were classified as non-Hispanic White, since the
large majority of these populations are expected to be White. In the Latin American study,
we categorized subjects as Latin American. For the Latin America study only, study center
was used as a proxy variable for race/ethnicity in all logistic regression models because each
center had an expected predominant ethnic group distribution.
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For subjects with missing data on education level (655 cases and 544 controls), we applied
multiple imputation with the PROC MI procedure in SAS statistical software 9.1. We
assumed that the education data were missing at random (MAR) with respect to unmeasured
covariates; whether or not education level was missing did not depend on any other
unobserved or missing values (22). We used a logistic regression model (23) to predict
education level for each of the geographic regions separately (North America, Europe, Latin
America) using age, sex, race/ethnicity, study, and case/control status as the covariates. The
logistic regression results to assess summary estimates for cigarettes and alcohol drinking
for five imputations were combined by using the PROC MIANALYZE procedure in SAS
statistical software.
Stratified analyses were conducted by cancer site (oral, pharynx, larynx), sex, age (<45
years, 45–60 years, ≥60 years), education (<high school, ≥high school), geographic region
(Europe, North America, Latin America), type of controls (hospital-based, population-
based), study size (<500 cases, ≥500 cases), BMI 2 to 5 years before diagnosis (<18.5 kg/
m2, 18.5 –<25 kg/m2, 25 – <30 kg/m2, ≥30 kg/m2) and BMI at age 20 or 30 and after
restriction to squamous cell carcinoma cases.
The population attributable risks (PAR) were estimated based on the formula AF = p(ec) ×
(OR−1)/OR, where p(ec)is the proportion exposed among the cases (24). Odds ratios
adjusted for potential confounding factors were used in these equations. The confidence
intervals for the AFs were calculated from the lower and upper limit ORs. The PAR for
tobacco and/or alcohol exposures (PARtotal) were estimated with the equation below where
a00=never tobacco/never alcohol users, a01= never tobacco/ever alcohol users, a10= ever
tobacco/never alcohol users, and a11=ever tobacco/ever alcohol users, m = total number of
cases.
ORs from multivariate analysis were used. The PARs for the tobacco and alcohol were
estimated as (31):
Results
Characteristics of cases and controls are shown in Table 1. The Latin America and New
York multicenter studies contributed the largest proportion of cases. There were a higher
proportion of men among cases compared to the controls. The majority of cases and controls
were European in ethnic origin. Cases had completed lower levels of education than the
controls.
The odds ratios were 2.37 (95%CI=1.66–3.39) for ever tobacco use among never alcohol
drinkers, 1.06 (95%CI=0.88–1.28) for ever alcohol use among never tobacco users, and 5.73
(95%CI=3.62–9.06) for the joint effect according to the random effects model (results not
shown). Thus, the joint effect between tobacco and alcohol was greater than expected under
the multiplicative model for all head and neck cancers (ψ=2.15, 95%CI=1.53–3.04; Table
2). The ψ from the random effects model was not exactly equal to that calculated from the
joint effects estimates (5.73/(2.37*1.06) = 2.28 ≠ 2.15), possibly due to the coefficient
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allowing for unknown sources of heterogeneity in the random effects models. For the fixed
effects model, the ORs were 2.17 for ever tobacco use among never alcohol drinkers, 0.98
for ever alcohol use among never tobacco users, 5.04 for the joint effect and 2.38 for the ψ.
Thus the ψ calculated from the joint effects was similar to that of the ψ from the model
(5.04/(2.17*0.98) = 2.37 ≈ 2.38).
By subsite, joint effects greater than multiplicative were observed for oral cavity cancer
(ψ=3.09, 95%CI=1.82–5.23) and pharyngeal cancer (ψ=1.90, 95%CI=1.41–2.56; Table 2).
For laryngeal cancer, the ψ was consistent with an interaction that is greater than
multiplicative but the confidence interval included the null value (ψ=1.62, 95%CI=0.85–
3.09). A more than additive interaction was detected between tobacco and alcohol for
laryngeal cancer risk (RERI=4.97, 95%CI=3.16–6.78; AP=0.42, 95%CI=0.32–0.52;
SI=1.85, 95%CI=1.50–2.26; data not shown). The study specific ψs are shown for head and
neck cancer in Figure 1 and for the subsites in supplementary figures S1–S3. Statistically
significant differences were not observed in the ψs for head and neck cancer, oral cavity
cancer, pharyngeal cancer or laryngeal cancer, in the different strata of education, study size,
source of controls or BMI (results not shown). The analysis restricted to SCCs (8034 cases)
resulted in a ψ similar to the overall analysis (ψ=2.27, 95%CI=1.52–3.38). Adjustment for
family history of head and neck cancer or ever passive smoking did not alter the magnitude
of the iORs.
The population attributable risk (PAR) for tobacco and alcohol, alone and overlapped was
72% (95%CI=61–79) for head and neck cancer, of which 4% was for alcohol alone, 33%
was for tobacco alone and 35% was for overlap between tobacco and alcohol (Table 2).
Comparing across cancer subsites, the PAR for oral cavity cancer was lower (64%,
95%CI=45–75) than for laryngeal cancer (89%, 95%CI=82–92), while the PAR for
pharyngeal cancer was intermediate to those of oral cavity and laryngeal cancer. For women,
the PAR for head and neck cancer, appeared to be lower than for men. The overall PAR is
probably closer to the PAR for men since the majority of cases and controls are men. The
PARs due to the overlap of tobacco and alcohol were greater than the PARs due to the
effects of tobacco alone on the risk of head and neck cancer among men, but not for women.
The estimated PAR due to the effect of alcohol alone was negative for oral cavity, although
as indicated by the CIs, this is consistent with either no effect of alcohol alone (PAR=0%) or
a very small effect.
When stratified by age and by geographic region, the ψs were fairly similar across age strata,
but the PARs were substantially lower among subjects <45 years of age compared to
subjects who were 45 or older. The PARs were also lower in North America, relative to the
PARs in Europe and Latin America.
In Table 3, the odds ratios and PARs for head and neck cancer by tobacco and alcohol
frequency categories are shown. The cancer risk was greatest for individuals in the high
frequency categories for tobacco and alcohol use. An interaction was suggested between the
frequency of tobacco and alcohol use on the risk of head and neck cancer (p<0.01), oral
cavity cancer (p<0.01), pharyngeal cancer (p<0.01), but not on the risk of laryngeal cancer
(p=0.63). The PARs indicate that the greatest proportion of the head and neck cancers were
attributable to heavy drinking (≥3 drinks/day) among smokers.
Discussion
Our results confirm a greater than multiplicative joint effect between tobacco and alcohol on
head and neck cancer risk, particularly for oral and pharyngeal cancers. Heterogeneity in the
multiplicative interaction parameters was not detected in the analysis stratified by anatomic
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subsite, sex, education level, geographic region, or BMI. Tobacco smoking and alcohol
drinking are responsible for a large proportion of oral and pharyngeal cancers, and an even
greater proportion of laryngeal cancers. Additionally, tobacco smoking and alcohol drinking
account for a higher proportion of head and neck cancers among men than among women.
Generally for men, tobacco and alcohol combined accounted for a larger proportion of cases
than smoking or drinking alone, while for women the effect of tobacco alone accounted for a
larger proportion of cases than the overlap between tobacco and alcohol, or alcohol alone.
Our estimates for PARs are consistent with previous estimates from a large-scale case-
control study on oral and pharyngeal cancers (not included in current INHANCE dataset)
which reported PARs of 80% for men, 61% for women and 74% overall (25). It will be
important to determine the risk factors for at least 28% of head and neck cancer patients
(42% for women, 26% for men) and specifically for at least 36% of oral cavity cancer
patients, whose cancer cannot be attributed to tobacco or alcohol.
The differences observed for the multiplicative interaction parameter did not necessarily
translate to differences in the PARs, or vice versa. The ψ appeared to be greater for oral
cavity cancer than for laryngeal cancer, but the PAR for oral cavity cancer was lower than
that of laryngeal cancer. The difference stemmed from the greater ORs observed for
laryngeal cancer for subjects who smoked tobacco (regardless of whether they drank alcohol
or not), relative to oral cavity and pharyngeal cancers. Similarly, although differences in the
ψs were not observed by geographic region, we observed a statistically significant lower
PAR for tobacco and alcohol in North America relative to Latin America and Europe. The
source of this difference may be the larger proportion of cases that drank alcohol and
smoked tobacco in Latin America and Europe in comparison to North America and the
higher ORs observed for tobacco and tobacco and alcohol combined. The difference in risk
for tobacco may reflect the differences in the types of cigarettes and tobacco used. This may
point to a more important role for other risk factors in North America. Studies of HPV in
North America provide some preliminary evidence that this may be true (26;27) in contrast
to a study including cases mostly from Europe(12).
Tobacco and alcohol appeared to be responsible for a smaller proportion of the head and
neck cancer cases in individuals who were younger (<45 years) compared to the older age
groups. The number of cases and controls in subjects <45 years was limited (though larger
than any previous study), as reflected in the odds ratio estimate for smoking tobacco. The
younger subjects also had a lower proportion of cases that drank alcohol and smoked
tobacco. It is possible that other head and neck cancer risk factors such as genetic
susceptibility, human papillomavirus infection or some nutritional factors are more
important risk factors in these groups, although further work is required to clarify this.
Though the PAR for the effect of alcohol alone was negative for oral cavity cancer and
among young subjects, this should not be interpreted as evidence that alcohol prevented any
cancers. The main effect OR for alcohol drinking overall and among never tobacco users
were not <1 for head and neck cancer or any of the subsites. In our previous analysis, we
showed that alcohol is an independent risk factor among never-tobacco users(20). The
confidence intervals of the PAR for the effect of alcohol alone generally included the null
value of 0%. These results suggest that either alcohol is acting only through its interaction
effect with tobacco or that the PAR of alcohol alone is minimal and difficult to detect
without greater statistical power. Significant PARs for the effect of alcohol alone were
detected for the larger case groups of head and neck cancer and pharyngeal cancer, favoring
the latter explanation.
There are several limitations in our pooled analysis. One potential source of bias is that
regional differences in social acceptance of tobacco and alcohol habits may have influenced
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how a subject responded to questions in a face-to-face interview. Our adjustment for study
center may have partially addressed this limitation. Recall bias was also a potential
limitation because in all of the studies the subjects knew their disease status when they were
interviewed. We explored whether there were differences in the ψ by the type of control
subjects (hospital-based or population-based), since hospital-based controls but not
population-based controls could also have a recall similar to that of cases depending on the
type of disease. The estimates by type of control were not different, suggesting a minimal
role for recall bias.
Another limitation is that we are unable to adjust for unmeasured potential confounders such
as HPV infection and nutritional factors. Low fruit and vegetable intake is a suspected risk
factor of head and neck cancer (28). However, low fruit intake and low vegetable intake may
increase risk by approximately 2 fold (29), which could not explain the magnitude of the
ORs observed in some of the higher combination categories of tobacco and alcohol intake. It
would be of interest to examine the three-way interaction for tobacco use, alcohol use and
low fruit and vegetable intake on head and neck cancer risk. HPV infection is thought to be
a stronger risk factor for oropharyngeal cancers (30), but the multiplicative interaction
parameters were not particularly stronger for pharyngeal cancer. However, our pharyngeal
group included hypopharyngeal cases in addition to oropharyngeal cases. Because
hypopharyngeal cancer has very strong associations with tobacco and alcohol, this may have
resulted in higher PARs than may have been seen for a pharyngeal group restricted to
oropharyngeal cancers. In any case, we believe it is unlikely that our results are due to
confounding by HPV. We hope to explore this area in the future when HPV data may be
available with a standardized measure across the INHANCE studies.
The major strength of our pooled analyses was the assembling of a very large series of head
and neck cancer patients and control subjects, which allowed us to examine in detail the
interaction between tobacco smoking and alcohol drinking, and explore differences in the
interaction by cancer subsite, geographic region, and sex. Our results confirm that the joint
effect between tobacco and alcohol is more than expected under the multiplicative model for
head and neck cancer and the oral and pharyngeal subsites. Tobacco and alcohol are
responsible for a large proportion of laryngeal cancers and head and neck cancer among
men. However, a substantial proportion of head and neck cancers cannot be attributed to
either tobacco or alcohol, particularly for oral cavity cancer, among women and below age
45.
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Appendix
Definition of tobacco and alcohol use
For cigarettes, ever smoking was defined as smoked ≥100 cigarette in a lifetime [Central
Europe, Los Angeles, North Carolina, Puerto Rico, Seattle, Houston and Boston studies];
smoked 1 cigarette/day for ≥1 year [International Multicenter, Tampa, Latin America,
Milan, Aviano, Italy multicenter, and Switzerland studies]; smoked ½ pack/week for ≥1
year [Iowa study], once a day for one years time [New York]; ever smoked [Rome study].
For cigars and pipes, ever smoking was defined as smoked cigars or pipes for ≥6 months
[Seattle, North Carolina, and Puerto Rico studies]; smoked 1 cigar or 1 pipeful of tobacco/
month for ≥6 months [Los Angeles study]; smoked 1 cigar or pipe/day for ≥1 year [Milan,
Aviano, Italy, Switzerland, Latin America]; smoked cigars or pipes “regularly” [Central
Europe studies]; once a day for 1 years time [New York study]; ever used cigars or pipes
[Houston study]); 1 cigar or 1 pipefuls of tobacco a week for ≥1 year [Iowa]; smoked daily
for >1 year [International multicenter study]; smoked a cigar or pipe once a day for ≥1 year
[Tampa study]; ever smoked 12 ounces of pipe tobacco or smoked 1 cigar/week for 1 year
[Boston study] and ever smoked cigars or pipes [Rome study].
The definitions of ever chewing and ever use of snuff differed across studies: ever use of
snuff or chew for ≥6 months [Seattle, North Carolina, and Puerto Rico studies]; 1 small can
of snuff or 1 pouch of chewing tobacco per week for ≥1 year [Iowa study]; use chew or
snuff once per day for ≥1 year [Tampa study]; chewed daily tobacco, betel quid, areca nut,
pan massala or snuffed tobacco daily for ≥1 year [International Multicenter studies]; 1 plug
of tobacco or 1 pinch of snuff of tobacco/month for ≥6 months [Los Angeles study]; at least
once a week for at least one year [New York]; ever use of snuff or chew [Houston and Rome
studies] and ever chewed smokeless tobacco [Boston study].
The definitions of ever alcohol drinking were: ‘ever’ consumed alcohol [Central Europe,
Aviano, Milan, Italy Multicenter, Switzerland, New York, Boston and Rome studies]; >4
drinks in a year [Seattle study]; ≥1 drink/month for ≥6 months in a lifetime [Los Angeles
study); ≥12 drinks of any kind of alcohol in a lifetime [Puerto Rico study]; ≥once/month
(Multicenter, Latin America studies); average ≥1 drink/week for ≥1 year [Iowa study];
once/week for ≥1 year [Tampa & Houston study]; ≥4 times/month of beer, wine or liquor
(North Carolina study).
Pooling alcohol variables
The volume specification for alcoholic beverages by type differed across studies. For
example, a glass of wine was defined as 100–150 mL in the European studies, whereas the
North American studies defined a wine glass as 3.6–5 ounces. To estimate cumulative
alcohol consumption (mL of beverage over a lifetime) for each beverage type, we converted
into milliliters the beverage volume specified in the questionnaire for the alcoholic beverage
type and multiplied this value by the number of beverage type consumed per week and the
duration of beverage type consumption reported. We then applied the volume percentage of
pure ethanol by beverage type [5% for beer, 12% for wine, 40% for liquor and 40% for
aperitifs to the beverage volume(32)], to estimate the cumulative consumption of pure
ethanol for each subject in mL. We then divided the cumulative consumption of pure ethanol
by 15.6 mL, the mean volume of pure ethanol per drink across all alcoholic beverage types
for the 15 studies, to calculate the lifetime number of standardized drinks consumed for each
subject (ie, one standardized drink contains 15.6 mL of pure ethanol). For the overall
frequency of alcohol drinking (i.e., the number of drinks/day), the frequency of consumption
of each alcoholic beverage type was weighted by the corresponding duration. For the Iowa
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and Tampa studies, data on duration by type of alcoholic beverage were not available, thus
the average of the frequency of all alcoholic beverage types within those studies was used as
the overall frequency.
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Figure 1.
Multiplicative interaction parameters (ψ) for tobacco (cigarette, cigar, pipe, snuff, chewing
tobacco) and alcohol study and combined, using INHANCE pooled data version 1.1. ORs
used to calculate ψ were adjusted for age, sex, race/ethnicity, education level.
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Table 1
Selected characteristics of head and neck cancer cases and controls
Cases Controls
n % n %
TOTAL 11221 16168
Study
Milan 416 3.7 1531 9.5
Aviano 482 4.3 855 5.3
Italy Multicenter 1058 9.4 2579 16.0
Switzerland 516 4.6 883 5.5
Central Europe Multicenter 762 6.8 907 5.6
Rome 275 2.5 294 1.8
New York Multicenter 1118 10.0 906 5.6
Seattle 407 3.6 607 3.8
Iowa 546 4.9 759 4.7
North Carolina 180 1.6 202 1.2
Tampa 207 1.8 897 5.5
Los Angeles 417 3.7 1005 6.2
Texas 829 7.4 865 5.4
Boston 584 5.2 659 4.1
Puerto Rico 350 3.1 521 3.2
Latin America Multicenter 2191 19.5 1706 10.6
IARC Multicenter1 883 7.9 992 6.1
Age
<40 415 3.7 1023 6.3
40–44 629 5.6 1151 7.1
45–49 1223 10.9 1800 11.1
50–54 1714 15.3 2487 15.4
55–59 2096 18.7 2801 17.3
60–64 1901 16.9 2531 15.7
65–69 1555 13.9 2064 12.8
70–74 1024 9.1 1517 9.4
≥75 664 5.9 794 4.9
Sex
Women 2256 20.1 4557 28.2
Men 8965 79.9 11611 71.8
Race/ethnicity
White 8272 73.7 13358 82.6
Black 403 3.6 485 3.0
Hispanic 164 1.5 350 2.2
Asian/Pacific Islanders 53 0.5 86 0.5
Other 138 1.2 183 1.1
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Cases Controls
n % n %
Latin American 2191 19.5 1706 10.6
Education
None 93 0.8 106 0.7
<Junior high school 4347 38.7 6169 38.2
Some high school 1576 14.0 1784 11.0
High School Graduate 1765 15.7 2163 13.4
Vocational, some college 1368 12.2 2514 15.5
≥College 1417 12.6 2888 17.9
Missing 655 5.8 544 3.4
Subtype
Oral 2993 26.7
Pharynx 4040 36.0
Oral/Pharynx NOS 917 8.2
Larynx 2965 26.4
H&N NOS 306 2.7
1
We excluded the Sudan (100 cases and 102 controls) and India (576 cases and 582 controls) centers of the International Multicenter study because
the Asia and Africa regions are not well represented for estimation of population attributable risks.
2
Information on ethnicity was not collected in the Central Europe and Latin America studies. In the Central Europe study, all subjects were
classified as non-Hispanic White, since the large majority of these populations are expected to be White. In the Latin American study, we
categorized subjects as Latin American.
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